08th week of 2012 patent applcation highlights part 31 |
Patent application number | Title | Published |
20120045431 | METHOD OF STABILIZING AND STERILIZING PEPTIDES OR PROTEINS - The present invention provides a method for sterilizing a protein-containing bioerodible implant. The sterilization is accomplished using β-radiation, or high energy electrons. Following sterilization the implant can be used in a variety of methods for the sustained release of a therapeutic protein to treat a disease or condition in a human or non-human subject. The sterilization process is compatible with proteins containing one or more disulfide bonds or easily oxidized methionine residues. | 2012-02-23 |
20120045432 | B LYMPHOCYTE STIMULATOR ASSAYS - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention. | 2012-02-23 |
20120045433 | COMBINATION THERAPY - The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an topoisomerase inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the topoisomerase inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof, and the disorder is colorectal cancer involving a tumor comprising b-Raf having the V600E mutation. | 2012-02-23 |
20120045434 | COMBINATION THERAPY - The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. | 2012-02-23 |
20120045435 | COMPOSITIONS AND METHODS TO INHIBIT STEM CELL AND PROGENITOR CELL BINDING TO LYMPHOID TISSUE AND FOR REGENERATING GERMINAL CENTERS IN LYMPHATIC TISSUES - The present invention relates to compositions and methods of inhibiting stem cell binding to organs and tissues, including the blocking of stem cell binding to germinal centers present in lymph tissue. Disclosed are compositions and methods for regenerating germinal centers in lymphatic tissue. Included in the compositions are adjuvants, agonists to CD40, CD28 and the IL-21 receptor, and antagonist to CD20. | 2012-02-23 |
20120045436 | Humanized Anti-CD70 Binding Agents and Uses Thereof - Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions. | 2012-02-23 |
20120045437 | MONOCLONAL ANTIBODIES THAT INHIBIT THE Wnt SIGNALING PATHWAY AND METHODS OF PRODUCTION AND USE THEREOF - Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed. | 2012-02-23 |
20120045438 | ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications. | 2012-02-23 |
20120045439 | TUMOR MARKERS AND METHODS OF USE THEREOF - The invention provides newly identified proteins as markers for the detection of tumors, or as targets for their treatment, particularly of tumors affecting lung, colon, breast, ovary; affinity ligands capable of selectively interacting with the newly identified markers; methods of screening a tissue sample for malignancy, for determining the presence of a tumor in a subject and for screening a test compound as an antitumor candidate; a diagnostic kit. | 2012-02-23 |
20120045440 | METHOD OF TREATING RHEUMATOID ARTHRITIS WITH AN ANTI-IL-6R ANTIBODY - The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof. | 2012-02-23 |
20120045441 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES - A method of treating an inflammatory disease in a subject in need thereof is carried out by administering the subject a gastrin-releasing peptide (GRP) inhibitor in a treatment effective amount. Suitable GRP inhibitors include compounds of the general formula (I) and pharmaceutically acceptable salt or prodrugs thereof. | 2012-02-23 |
20120045442 | HUMAN MONOCLONAL ANTIBODIES TO CTLA-4 - In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein. | 2012-02-23 |
20120045443 | Agonist anti-trk-c monoclonal antibodies - The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy. | 2012-02-23 |
20120045444 | Treatment for Neoplastic Diseases - Administration of a mAb that specifically binds IL-1α is useful for treating tumor-associated diseases in human subjects. | 2012-02-23 |
20120045445 | METHOD OF TREATING VIRAL DISEASES - A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance with homeopathic technology. In order to obtain antibodies, human or heterologous interferon alpha, beta, or gamma, including recombinant interferon, is used; a mixture of various, mostly centimal, homeopathic dilutions being employed. A method of treating a pathologic syndrome, whose formation is affected by interferon, consists in the use of activated forms of antibodies to interferon alpha, beta, or gamma in low or ultra-low doses obtained by multiple consecutive dilutions and exposure to external factors. | 2012-02-23 |
20120045446 | THERAPEUTIC AGENT FOR DISEASES IN WHICH NEOPLASTIC PROLIFERATION OF PLASMA CELLS OCCURS - The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes:
| 2012-02-23 |
20120045447 | T CELL COSTIMULATING POLYPEPTIDES AND USES THEREOF - A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system. | 2012-02-23 |
20120045448 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS - Compounds of the disclosure provide compositions, which are effective for prophylaxis and treatment of diseases or disorders, such as cell-proliferation, angiogenesis, or apoptosis mediated diseases. The disclosure encompasses compounds, analogs, prodrugs, metabolites, and pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer, tumors, and like conditions. The disclosure also provides therapeutic methods including the administration of an effective amount of a compound of the disclosure. | 2012-02-23 |
20120045449 | COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR EARLY INTERVENTION IN BONE MARROW TRANSPLANTATION AND TREATMENT OF GRAFT VERSUS HOST DISEASE - Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (α1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT. | 2012-02-23 |
20120045450 | METHOD FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS - M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal. | 2012-02-23 |
20120045451 | Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM - This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity. | 2012-02-23 |
20120045452 | Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM - This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction. | 2012-02-23 |
20120045453 | Anti-IL-6 Antibodies, Compositions, Methods and Uses - An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 2012-02-23 |
20120045454 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES - The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. | 2012-02-23 |
20120045455 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS - Methods of using phosphotetrahydropyran compounds for treatment of fibrotic and scarring disorders, e.g. pulmonary fibrosis, fibrosis associated with surgical procedures, wound healing disorders, scar formation, sclerotic disorders, ocular fibrotic disorders, ocular healing disorders, ocular fibrosis after surgery, glaucoma, tendon scarring disorders, joint scarring disorders, kidney interstitial fibrosis and glomerular fibrosis and tubular fibrosis of the kidney. | 2012-02-23 |
20120045456 | STABILIZED ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY FORMULATIONS - The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention. | 2012-02-23 |
20120045457 | NONTYPABLE HAEMOPHILUS INFLUENZAE ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable | 2012-02-23 |
20120045458 | USE OF NOTCH REGULATORS FOR MODULATING THE IMMUNE RESPONSE BY INDUCTION/SUPPRESSION OF INTERLEUKIN-22 - The invention relates to the use of notch regulators for modulating IL-22 production in T-cells, by influencing the activity or activation of the notch signal path. The invention further relates to the use of modulating the immune response, primarily in case of infection reactions. The invention in particular relates to the use for treating illnesses associated with infections. The invention further relates to the use for reducing IL-22 production in T-cells. | 2012-02-23 |
20120045459 | Methods for Treating Autophagy-Related Disorders - Methods for treating autophagy-related disorders with agents which modulate expression of the gene encoding tyrosine phosphatase receptor type sigma (PTPRS) or which modulate the biological activity of the PTPRS gene product (PTPsigma). Methods for modulating autophagy in a cell with agents which modulate expression of PTPRS or which modulate the biological activity of PTPsigma; and related diagnostic methods, screening methods, and agents. | 2012-02-23 |
20120045460 | METHODS AND COMPOSITIONS FOR TREATMENT OF GRAFT REJECTION AND PROMOTION OF GRAFT SURVIVAL - Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In certain embodiments, compositions and methods relate to inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection, islet cell preservation and conditions commonly associated with graft rejection. Other embodiments relate to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities. | 2012-02-23 |
20120045461 | Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs - Tis invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals. | 2012-02-23 |
20120045462 | Inflammation Inhibiting Compounds - The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of αMSH for inducing tolerance. | 2012-02-23 |
20120045463 | Methods and compositions comprising supramolecular constructs - The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P | 2012-02-23 |
20120045464 | CRYPTOSPORIDIUM PARVUM ANTIGENS, ANTIBODIES THERETO AND DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS THEREOF - Cloning and expression of genes encoding | 2012-02-23 |
20120045465 | CANCER ANTIGEN HELPER PEPTIDE - The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like. | 2012-02-23 |
20120045466 | IDENTIFICATION OF ANTIGENIC PEPTIDES FROM MULTIPLE MYELOMA CELLS - Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines. | 2012-02-23 |
20120045467 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE - The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount. | 2012-02-23 |
20120045468 | Immunogenic Compositions and Uses Thereof - Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods. | 2012-02-23 |
20120045469 | VACCINE - The present invention provides an immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising an oil-in-water emulsion. | 2012-02-23 |
20120045470 | IMATINIB IMMUNOASSAY - Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids. | 2012-02-23 |
20120045471 | RECOMBINANT PARAINFLUENZA VIRUS VACCINE COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human | 2012-02-23 |
20120045472 | Biochemically Stabilized HIV-1 ENV Trimer Vaccine - Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. | 2012-02-23 |
20120045473 | Biomolecule Surface Display and Uses Thereof - A vaccine for the treatment or prevention of a disease in a subject, wherein said disease is associated with an avian influenza virus, and wherein said vaccine comprises an expression vector comprising a nucleic acid encoding a hemagglutinin peptide, such that in use said hemagglutinin peptide is expressed by said expression vector in said subject. | 2012-02-23 |
20120045474 | Substrate peptide sequences for plague plasminogen activator and uses thereof - The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes | 2012-02-23 |
20120045475 | LIVE ATTENUATED VACCINES - The present invention relates to a bacterium attenuated by a mutation in at least one ABC transporter gene wherein the mutation renders the corresponding ABC transporter protein non-functional and wherein the attenuated bacterium persists in a subject. | 2012-02-23 |
20120045476 | LIVE ATTENUATED MYCOPLASMA STRAINS - The present invention provides live, attenuated | 2012-02-23 |
20120045477 | Method for Treating Cancer with Toxoplasma Gondii Vaccine - The present invention provides attenuated | 2012-02-23 |
20120045478 | METHOD AND COMPOSITIONS - A method of preparing a compound of formula (III): wherein x is from 1 to 6, y is from 1 to 12, z is from 0 to 10, each M and each M′ is independently a mycolic acid residue including a β-hydroxy acid moiety and each S is a monosaccharide unit; the method comprising reacting one or more mycolic acids with one or more saccharide units wherein the hydroxyl group of each β-hydroxy acid moiety is protected prior to reaction with the one or more saccharide units. | 2012-02-23 |
20120045479 | Dry Powder Formulations, Vaccines and Methods - Respirable dry powder formulations comprise myo-inositol and leucine. Dry powder human papillomavirus (HPV) vaccine formulations comprise a least one HPV capsid protein and a carrier comprising myo-inositol and leucine. Methods of administering an HPV vaccine to an individual comprise inhalation administration to the individual of a dry powder HPV vaccine formulation comprising a least one HPV capsid protein and a carrier comprising myo-inositol and leucine. | 2012-02-23 |
20120045480 | COMPOSITION COMPRISING SILVER NANOPARTICLES AND EXTRACTS OF POLYGONUM MULTIFLORUM THUNB AND THE USE THEREOF - A pharmaceutical composition comprising effective amount of silver nanoparticles and extracts of | 2012-02-23 |
20120045481 | PREVENTIVE AND/OR AMELIORATIVE AGENT FOR DISEASES, STAMINA ENHANCEMENT AGENT, ANTI-FATIGUE AGENT, AND PHARMACEUTICAL AND FOOD AND DRINK USING THEM - A purple non-sulfur bacteria useful in preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and having high safety is provided. A preventive and/or ameliorative agent is for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and includes at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria. The purple non-sulfur bacteria includes | 2012-02-23 |
20120045482 | POLICOSANOL NANOPARTICLES - The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions. | 2012-02-23 |
20120045483 | Mannitol and/or Proline for Prevention and Treatment of Ageing Related Symptoms - The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses Mannitol 5 and/or proline containing compositions that are particularly useful for the treatment of premature ageing related symptoms in mammalian subjects suffering from genetic defects in DNA damage response and genome maintenance pathways. Humans suffering from Cockayne syndrome (CS), Xerodema pigmentosum (XP), combined XPCS, trichothiodystrophy (TTD), COFS (cerebro-oculo-facio-skeletal syndrome), 10 XFE disorder (Xpf-Erccl syndrome), Bloom Syndrome (BS), Werner Syndrome (WS), Ataxia telangiectasia (AT), Fanconi Anemia (FA), Hutchinson Guilford Progeria (HGP) may be treated with pharmaceutical compositions comprising mannitol and/or proline according to this invention. | 2012-02-23 |
20120045484 | CALCIUM PHOSPHATE/SULFATE-BASED BONE IMPLANT COMPOSITION - A bone graft composition includes beta-tricalcium phosphate and calcium sulphate and slowly soluble sources of calcium ions and hydroxyl ions. | 2012-02-23 |
20120045485 | SUSTAINED RELEASE DOSAGE FORM - An osmotic dosage form which comprising:
| 2012-02-23 |
20120045486 | DELIVERY SYSTEMS - The present invention provides a delivery system for active and functional ingredients. In particular, the delivery systems of the present invention find particular application in the delivery of active and functional ingredients, such as medicaments, pharmaceuticals, nutritional supplements, botanicals, cosmeceuticals etc. Further, the invention relates to a delivery system for oral or topical administration of such active and functional ingredients. The invention is a delivery system based on a particulate gel precursor that acts both as the bodying agent,as well as the dispersing and suspending agent in the formulation. By modifying the level of precursor and process conditions, a broad range of product consistencies can be achieved ranging from thin liquid suspension to firm or semi solid gel. The precursor gel is a particulate linear chain fuctan gel. Inulin is a preferred fructan. | 2012-02-23 |
20120045487 | MULTIPHASIC MICROFIBERS FOR SPATIALLY GUIDED CELL GROWTH - A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and is formed by electrohydrodynamic jetting. Further, such microfibers optionally have one or more biofunctional agents, which may be surface-bound moieties provided in spatial patterns. Multiphasic microfibers formed in accordance with the disclosure may form, in some cases, three-dimensional fiber scaffolds with precisely engineered, micrometer-scaled patterns for cellular contact guidance, which may thus support and/or promote cellular growth, proliferation, differentiation, repair, and/or regeneration for tissue and bioengineering applications. | 2012-02-23 |
20120045488 | COMPRESSED SOLID DOSAGE FORM MANUFACTURING PROCESS WELL-SUITED FOR USE WITH DRUGS OF LOW AQUEOUS SOLUBILITY AND COMPRESSED SOLID DOSAGE FORMS MADE THEREBY - A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing the blend into a solid, comminuting the solid into granules, wetting the granules, drying the granules, and tabletting the dried granules to make a solid pharmaceutical formulation. | 2012-02-23 |
20120045489 | Nano-Emulsion Injection of Vinca Alkaloids and the Preparation Method Thereof - A nano-emulsion injection of Vinca alkaloids and its preparation method are disclosed. The injection is an oil-in-water emulsion injection comprising Vinca alkaloids or their salts, injectable oil, surfactant(s) and injectable water, wherein the average diameter of the droplets of the emulsion is less than 100 nm and the pH of the emulsion is 7-9. The preparation method comprises the steps of preparing the oil phase and the aqueous phase respectively, homogeneously mixing the oil phase and the aqueous phase with high speed, adding the active ingredient, adjusting the pH to 7-9, adding water to constant volume, and homogenizing the emulsion till the average diameter of the droplets being less than 100 nm. The alternative method comprises the steps of homogeneously mixing the oil phase and the aqueous phase, homogenizing the obtained emulsion under high pressure till the average diameter of the droplets being less than 100 nm, adding the active ingredient, adjusting the pH to 7-9, stirring, and adding water to constant volume. | 2012-02-23 |
20120045490 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF - Provided are compositions comprising an extract of | 2012-02-23 |
20120045491 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF - Provided are compositions comprising an extract of | 2012-02-23 |
20120045492 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF - Provided are compositions comprising an extract of | 2012-02-23 |
20120045493 | Solid Cosmetic Composition with Structurant and Electrolyte Solution - A water soluble cosmetic or pharmaceutical or pharmaceutical actives in an electrolyte solution which, when impregnated with one or more retentive fillers (such as, for example, silica or hydrophobically modified silica, lamellar filler, crosspolymer, cellulosic, resins, or silicone elastomers) can form stable solid compositions with structurants. Such solid compositions do not require a higher buffer pH or leave residues upon application to the skin. Solid compositions according to the present invention are suitable for cosmetic and pharmaceutical purposes such as antiperspirants, deodorants, lip products, and other topical applications. | 2012-02-23 |
20120045494 | Gum Base - The present invention relates to a chewing gum base for use in chewing gum compositions wherein the chewing gum base contributes to the ability of the chewing gum compositions and products to degrade over time after chewing due to environmental influences or cleaning processes, while at the same time providing a significant shelf life for the final chewing gum composition product. The chewing gum base comprises a hydrophilic precursor component comprising hydrolysable units and an elastomer, wherein the hydrophilic precursor component comprising hydrolysable units is encapsulated or dispersed in a barrier material. Moreover, the invention relates to chewing gum compositions containing such chewing gum bases. | 2012-02-23 |
20120045495 | HIGHER LOADING ZINC-CONTAINING FILMS - Described herein are polymer matrix films, compositions comprising the polymer matrix films, and methods of preparing and using the same. | 2012-02-23 |
20120045496 | IONIZED PERFORMANCE FABRIC WITH ANTIMICROBIAL/ANTIBACTERIAL/ANTIFUNGAL PROPERTIES - A composition for treating fabric includes about 0.1 to about 10.0% cross linking agent, about 0.1 to about 5.0% of a material selected from a group consisting of oxidized polyolefin, polyolefin and mixtures thereof, about 0.1 to about 0.5% wetting agent, about 1.0 to about 14.0% of a material selected from a group consisting of aminofunctional silicone, ionizing agent and mixtures thereof, about 0.0 to about 2.0% catalyst, about 1.0 to about 3.0% antimicrobial/antibacterial/antifungal agent and any remainder as a carrier. The composition has a pH of between about 2.0 to about 4.0. A performance fabric treated with the composition and a method of treating a performance fabric are also provided. | 2012-02-23 |
20120045497 | PESTICIDAL COMBINATIONS - Stabilized liquid agrochemical compositions are provided which comprise flowable non-aqueous dispersion concentrates comprising a continuous substantially water-miscible liquid phase, a dispersed water-immiscible liquid phase, and a colloidal solid. In one embodiment, the dispersed phase comprises at least one water-sensitive agrochemically active ingredient and the colloidal solid is disposed at the interface between the dispersed phase and the continuous phase. In another embodiment, the water-sensitive agrochemically active ingredient is a solid but is dissolved in an oily liquid present in the dispersed phase, or is a solid and is dispersed within the dispersed phase, or is a solid complex of an agrochemical with a molecular complexing agent and is dispersed within the dispersed phase. The compositions of the invention can be used directly or with dilution to combat pests or as plant growth regulators. | 2012-02-23 |
20120045498 | ANTIMICROBIAL COATING SYSTEM - An antimicrobial coating system, a film-forming composition, and an antimicrobial film. In some embodiments, the antimicrobial coating system can include a film-forming composition comprising a polymer having an effective molecular weight, and an effective amount of an antimicrobial agent dispersed within the polymer. The film-forming composition can form a water-insoluble, biocidal antimicrobial film when applied to a surface. | 2012-02-23 |
20120045499 | PEARLESCENT PIGMENT SURFACE TREATMENT FOR CONFECTIONERY - A confection with unique visual impression is created by partially treating the surface area of the confection with a coating composition including a pearlescent pigment such that the initial taste perception of the confection is not adversely affected by the coating composition. | 2012-02-23 |
20120045500 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general formula (I): | 2012-02-23 |
20120045501 | CONNEXIN ENHANCES CHEMOTHERAPY-INCLUDED APOPTOSIS IN HUMAN CANCER CELLS INHIBITING TUMOR CELL PROLIFERATION - The present invention provides methods and compositions for the inhibition of proliferation rate of target cells, for example tumor cells. In particular, a nucleic acid encoding a connexin protein, fragment, derivative or analog thereof can be incorporated into a target cell. Expression of the nucleic acid sequence encoding the connexin protein, fragment, derivative or analog thereof, particularly connexin 43 and non-phosphorylated connexin 43, reduces the level of bc1-2 expression in the cells thereby inducing the cells to enter apoptosis. Connexin protein, fragments, derivatives, or analogs thereof can also be administered to the cell population to reduce bc1-2 expression inducing apoptosis in the cell population. It has further been found that the addition of an antagonist of MCP-1 activity can enhance the effects of connexin on tumor cell proliferation. Also, the prognosis of a subject undergoing standard chemotherapy can be assessed by correlating the expression levels of connexin and bc1-2. | 2012-02-23 |
20120045502 | ANTAGONISTS OF MUC1 - The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics. | 2012-02-23 |
20120045503 | Compositions And Methods For Wound Healing - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osteoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues. | 2012-02-23 |
20120045504 | ORAL DRUG DEVICES AND DRUG FORMULATIONS - Compositions containing a drug to be delivered and at least one chemical permeation enhancer (CPE), and methods of making and using these compositions are described herein. In a preferred embodiment, the compositions contain two or more CPEs which behave in synergy to increase the permeability of the epithelium, while providing an acceptably low level of cytotoxicity to the cells. The concentration of the one or more CPEs is selected to provide the greatest amount of overall potential (OP). Additionally, the CPEs are selected based on the treatment. CPEs that behave primarily by transcellular transport are preferred for delivering drugs into epithelial cells. CPEs that behave primarily by paracellular transport are preferred for delivering drugs through epithelial cells. Also provided herein are mucoadhesive oral dosage forms. In a preferred embodiment, the oral dosage form is a multi-compartmental device, containing (i) a supporting compartment, (ii) drug compartment and (iii) mucoadhesive compartment. | 2012-02-23 |
20120045505 | FIXED DOSE DRUG COMBINATION FORMULATIONS - Pharmaceutical formulations comprising multiple drugs, for treating or preventing cardiovascular disease. Embodiments are capsules containing individual drugs, or combinations of drugs, in the form of small tablets. | 2012-02-23 |
20120045506 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING NEUTRAL VINYL POLYMERS AND EXCIPIENTS - The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.1 to 30% by weight of a plasticizer whereby the excipients of the excipients portion b) are each calculated on the dry weight of the polymer portion a). | 2012-02-23 |
20120045507 | STABLE SOFT CAPSULE DOSAGE FORM FOR ACETYLSALICYLIC ACID - A stable soft gel dosage form for acetylsalicylic acid (ASA), aspirin, is provided wherein soft gel capsules containing the ASA can be stored for prolonged periods under typical home storage conditions with better than 98% or 99% ASA integrity and with negligible physical or chemical deterioration of the soft gelatin capsule over the period of six months. A suspension of ASA in a monoglyceride component comprising more than about 50% glyceryl monooleate is packaged in a soft gelatin capsule, which can be substantially free of other components. The ASA in this composition is resistant to hydrolysis from water contained within the soft gelatin matrix or diffusing through the matrix. Methods of preparation and methods of use are also provided. | 2012-02-23 |
20120045508 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 2012-02-23 |
20120045509 | MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS - The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor. | 2012-02-23 |
20120045510 | TABLET SLEEVE FOR IMPROVED PERFORMANCE - A capsule-like dosage form, method for producing such dosage form and apparatus are disclosed. Such dosage form is achieved by applying a sleeve over the caplet to provide a coating which is smoother and easier to swallow than an uncoated caplet. The production of the capsule-like dosage form is readily facilitated by simple and inexpensive modifications to existing empty gelatin capsule making equipment. | 2012-02-23 |
20120045511 | THERMOSENSITIVE HEPATITIS B VACCINE - A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The thermosensitive hepatitis B vaccine of the disclosure is particularly suitable for being applied in the patients, which are low responsive or non-responsive to conventional hepatitis B vaccine, for enhancing the induction of cell-mediated immune responses and overcoming the HBsAg non-responsiveness. | 2012-02-23 |
20120045512 | METHODS AND SUBSTRATES FOR DIFFERENTIATION OF NEURAL STEM CELLS - The present invention is directed to methods and substrates for promoting the differentiation of neural stem cells to neurons. | 2012-02-23 |
20120045513 | POLYMER-BASED, SUSTAINED RELEASE DRUG DELIVERY SYSTEM - Disclosed is a sustained release system that includes a polymer and a pharmaceutically active agent dispersed in the polymer. The agent is in granular or particulate form, and has a rate of release from the system that is limited primarily by the rate at which the agent dissolves from the granules into the polymer matrix. Advantageously, the polymer is permeable to the agent and is non-release-rate-limiting with respect to the rate of release of the agent from the polymer. | 2012-02-23 |
20120045514 | ANTI-CANCER MICROPARTICLE - The present invention relates to a microparticle and its use. The microparticle has a width of at least about 1 micron. The microparticle includes a biocompatible polymer, a nanoparticle, and an anti-cancer agent. | 2012-02-23 |
20120045515 | HOLLOW SILICA PARTICLE WITH A POLYMER THEREON - The present invention provides a hollow silica micro- or nanoparticle with a polymer immobilized thereon. The polymer is covalently linked to the silica particle via urethane groups. Provided is also a method of covalently coupling a polymer to a silica surface. The method comprises contacting a silica surface that carries amino functional groups with a polymer with a carbonate group of the general Formula (2). R | 2012-02-23 |
20120045516 | COMPOSITION FOR PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE - A composition for photodynamic therapy including a polymer capsule having a diameter of about 10 nm to about 2000 nm synthesized by copolymerization of a flat aromatic compound represented by Formula 1 (see the specification) and an organic compound represented by Formula 2 (see the specification). | 2012-02-23 |
20120045517 | TREATMENT OF CELIAC DISEASE WITH IgA - A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. | 2012-02-23 |
20120045518 | ENHANCING COAGULATION OR REDUCING FIBRINOLYSIS - Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma). | 2012-02-23 |
20120045519 | USE OF DEOXYELEPHANTOPIN (DET) AND ANALOGUES THEREOF FOR TREATMENT OF MELANOMA - Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof. | 2012-02-23 |
20120045520 | PHARMACEUTICAL COMPOSITION COMPRISING ARSENITE FOR THE TREATMENT OF MALIGNANCY - A method for using a salt of meta-arsenite (AsO | 2012-02-23 |
20120045521 | SYNERGISTIC FUNGICIDAL AND ALGICIDAL COMPOSITIONS INCLUDING 2-HYDROXYPHENYLALDEHYDE AND 2-HYDROXYPHENYLKETONE HETEROCYCLOYLHYDRAZONES AND COPPER - The present invention relates to the use of mixtures containing 2-hydroxyphenylaldehyde and 2-hydroxyphenylketone heterocycloylhydrazone compounds and copper for controlling the growth of fungi and algae. | 2012-02-23 |
20120045522 | SYNERGISTIC FUNGICIDAL AND ALGICIDAL COMPOSITIONS INCLUDING 7-HYDROXY-INDANONE BENZOYLHYDRAZONES AND COPPER - The present invention relates to the use of mixtures containing 7-hydroxy-indanone benzoylhydrazone compounds and copper for controlling the growth of fungi and algae. | 2012-02-23 |
20120045523 | COMBINATION OF A TLR3 LIGAND AND A CHEMOTHERAPY AGENT WHICH ACTS ON THE INTRINSIC "APOPTOSIS" PATHWAY IN THE TREATMENT OF CANCER - The present invention relates to a drug comprising separately or together (i) a TLR3 ligand and (ii) a chemotherapeutic agent that acts on the intrinsic apoptotic pathway, for simultaneous or sequential administration in the treatment of cancer, wherein the chemotherapeutic agent is selected from topoisomerase II inhibitors, platinum-derived alkylating agents and PI3 kinase inhibitors. | 2012-02-23 |
20120045524 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 2012-02-23 |
20120045525 | MOSQUITO REPELLENT SOLUTION, PREPARATION METHOD AND USE THEREOF - A mosquito repellent solution to prevent mosquito bite, comprising 0.1-9.9% organic acid of total weight as active principle, 88-99.6% water as solvent. The organic acid is single acid or mixed composition out of ethyl butyrate, propionic acid, n-butyric acid, isobutyric acid, isobutyric, valeric acid, hexanoic acid, n-Heptanoic acid, L-Lactic Acid and malic acid. The composition solution to prevent mosquito bite disturb mosquitoes' olfactory sensation through imitating human's smell of skin and breath; all raw materials base on the standard of food grade, so the composition is safe to human beings, particularly to infant, pregnant women, children and the old who are weaker. The composition solution does not work by killing mosquitoes so it would not relate to resistance and ecology risk. The preparation method is simple with low costs; there is no three wastes and friendly to the environment. The composition solution applies to the preparation of preventing mosquito bite, relieving itching and detumescence, and air sterilization. | 2012-02-23 |
20120045526 | PHARMACEUTICAL COMPOUND WHICH INCLUDES CLINOPTILOLITE - This invention is for a compound for treating a human or animal body to relieve the symptoms of any one of chemical-, substance-, and medicine induced gastrointestinal tract irritation, the compound including clinoptilolite. The invention is also for a compound for treating a human or animal body to lower the incidences of gastic events in persons using non-steroidal, anti-inflammatory medications, the compound including clinoptilolite. | 2012-02-23 |
20120045527 | NEW INSECTICIDES FOR AGRICULTURAL AND HORTICULTURAL CROPS - Controlling insects of the superfamily of the Psylloidea in horticultural and/or agricultural crops, by using bicarbonate and carbonate salts. | 2012-02-23 |
20120045528 | USE OF N20 GAS FOR TREATING CHRONIC PAIN - The invention relates to a gas mixture that contains nitrous oxide (N | 2012-02-23 |
20120045530 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF - Provided are compositions comprising an extract of | 2012-02-23 |
20120045531 | METHODS OF TREATING CELLULITE - Provided are methods of treating cellulite, the methods comprising applying to skin in need of cellulite treatment a composition comprising paulownin or an extract of | 2012-02-23 |